FILL THE SHORT

  

STUDY -NEW CRASH FILL THE SHORT

ID	STOCK	DATE	TIME	AVG	AMT	CALCULATED	MARKET PRICE	nET LOSS	TOTAL LOSS	FILL PRICE	FILL AMOUNT	FILL TOTAL	TOTAL VALUE	TOTAL STOCK	FINAL AVG	REMARK
14	ATOS	10/26/2021	4:00:00 PM	$2.82	$54.12	$152.62	$2.64	($0.18)	($9.74)	$2.64	$500.00	$1,320.00	$1,472.62	$554.12	$2.66	(6.52% NET LOSS GAP 6 CENT )IF 3TIMES FILLED WILL BE GAP 5 CENT

 TO BUY ATHE (ATHE DOWN TODAY normally its running around 1.31 to 1.35 

STUDY -NEW CRASH FILL THE SHORT

ID	STOCK	DATE	TIME	AVG	AMT	CALCULATED	MARKET PRICE	nET LOSS	TOTAL LOSS	FILL PRICE	FILL AMOUNT	FILL TOTAL	TOTAL VALUE	TOTAL STOCK	FINAL AVG	REMARK
17	AGE	10/26/2021	4:00:00 AM	$1.47	$202.00	$296.94	$0.86	($0.61)	($123.06)	$0.86	$400.00	$344.32	$641.26	$602.00	$1.07	GAP 19CENT (FILL FROM 41%)CURRENT GAP 61CENT
18	AGE	10/26/2021	4:00:00 AM	$1.47	$202.00	$296.94	$0.86	($0.61)	($123.22)	$0.86	$800.00	$688.00	$984.94	$1,002.00	$0.98	GAP 13CENT (FILL FROM 41%)

STUDY -NEW CRASH FILL THE SHORT

ID	STOCK	DATE	TIME	AVG	AMT	CALCULATED	MARKET PRICE	nET LOSS	TOTAL LOSS	FILL PRICE	FILL AMOUNT	FILL TOTAL	TOTAL VALUE	TOTAL STOCK	FINAL AVG	REMARK
15	ACST			$6.12	$126.00	$771.12	$1.69	($4.43)	($558.18)	$1.69	$1,200.00	$2,028.00	$2,799.12	$1,326.00	$2.11

STUDY -NEW CRASH FILL THE SHORT

ID	STOCK	DATE	TIME	AVG	AMT	CALCULATED	MARKET PRICE	nET LOSS	TOTAL LOSS	FILL PRICE	FILL AMOUNT	FILL TOTAL	TOTAL VALUE	TOTAL STOCK	FINAL AVG	REMARK
15	ACST			$6.12	$126.00	$771.12	$1.69	($4.43)	($558.18)	$1.69	$5,000.00	$8,450.00	$9,221.12	$5,126.00	$1.80

STUDY -NEW CRASH FILL THE SHORT

ID	STOCK	DATE	TIME	AVG	AMT	CALCULATED	MARKET PRICE	nET LOSS	TOTAL LOSS	FILL PRICE	FILL AMOUNT	FILL TOTAL	TOTAL VALUE	TOTAL STOCK	FINAL AVG	REMARK
12	BBIG	10/26/2021	2:49:00 AM	$0.60	$53.00	$31.69	$0.44	($0.16)	($8.53)	$0.44	$500.00	$218.50	$250.19	$553.00	$0.45	(IF 3 TIMES 5CENT GAP) IF FOUR TIMES 4 CENT GAP (26PERCENT 10 TIMES 2 CENT GAP

STUDY -NEW CRASH FILL THE SHORT

ID	STOCK	DATE	TIME	AVG	AMT	CALCULATED	MARKET PRICE	nET LOSS	TOTAL LOSS	FILL PRICE	FILL AMOUNT	FILL TOTAL	TOTAL VALUE	TOTAL STOCK	FINAL AVG	REMARK
8	ATHE	10/26/2021	2:19:00 PM	$1.35	$22.00	$29.70	$1.23	($0.12)	($2.64)	$1.23	$44.00 DOUBLE COVER		$54.12	$83.82	$66.00	$1.27	2CENT GAP

STUDY -NEW CRASH FILL THE SHORT

ID	STOCK	DATE	TIME	AVG	AMT	CALCULATED	MARKET PRICE	nET LOSS	TOTAL LOSS	FILL PRICE	FILL AMOUNT	FILL TOTAL	TOTAL VALUE	TOTAL STOCK	FINAL AVG	REMARK
9	UTSI	10/26/2021     SELL OFF 1 SHARE PRICE STUDY	2:22:00 PM	$1.21	$1.10	$1.33	$1.30	$0.09	$0.10							SELL OFF TO GET IN AGAIN

BKR

 U.S. Oil-Rig Count Falls by Two in Latest Week, Baker Hughes Says

Mentioned:

BKR

By Dave Sebastian

The number of rigs drilling for oil in the U.S. fell by two in the latest week to 443, according to oil-field services company Baker Hughes Co.The oil-rig count was 232 higher than a year earlier, Baker Hughes said Friday.The nation's gas-rig count rose by one to 99 in the latest week, and was up by 26 compared with the same week last year.The U.S. offshore-rig count rose by one to 13 this week and is unchanged from the year-ago period.The U.S. oil-rig count is viewed as a proxy for activity in the sector. The metric peaked at 1,609 in October 2014.Global oil benchmark Brent crude rose to about $85.46 a barrel Friday. West Texas Intermediate crude, the U.S. benchmark, rose to about $83.64 a barrel.dave.sebastian@wsj.comWrite to Dave Sebastian at dave.sebastian@wsj.com

INFO

 Service-Sector Strength Aids Global Growth

Mentioned:

INFO

By Paul Hannon and David Harrison

Business activity accelerated in some of the world's largest economies owing to a pickup in the services sector that has offset weakness in manufacturing caused by supply-chain bottlenecks and rising prices.Surveys of purchasing managers conducted over recent weeks point to increased growth in the U.S., Japan and Australia due to easing fears of the Delta variant of Covid-19.In Europe, however, growth slowed due to reduced factory activity as businesses reported difficulties getting hold of the parts and raw materials they needed.That combination likely means the global economy will continue to recover in the final months of the year, but not at the pace reached in the second quarter, when reopenings led to a growth spurt.Private data firm IHS Markit said Friday that its composite Purchasing Managers Index for the U.S. rose to a three-month high of 57.3 in October from 55 in September. A reading above 50 indicates growth, while a level below 50 signals contraction.In the eurozone, the PMI fell to a six-month low of 54.3 in October from 56.2 in September. U.S. growth was driven by the service sector, which hired at the quickest pace since June, the IHS survey showed. Businesses said they were struggling to meet increased demand because of supply-chain backups and a shortage of available workers. Manufacturing activity in the U.S. slowed in October with firms reporting longer delivery times. Figures for gross domestic product to be released in the U.S. and Europe next week are expected to point to a slowdown in the three months through September. Economists surveyed by The Wall Street Journal expect the U.S. economy grew at a seasonally adjusted annual rate of 3.1% in the third quarter, down from 6.7% in the second quarter.China reported a sharp slowdownEarlier this week, China reported a sharp slowdown in growth in the third quarter, when the economy expanded 4.9%, compared with 7.9% during the previous three months, in part due to supply-chain problems and energy shortages.Input prices rose steeply because of supply problems, higher labor and shipping costs and a shortage of raw materials. The U.S. consumer-price index rose 5.4% in September from the previous year, the Labor Department reported earlier this month.'While the economy looks set for stronger growth in the fourth quarter, the upward rise in inflation pressures also shows no sign of abating,' said Chris Williamson, chief business economist at IHS Markit. hit a 13-year highFor European factories, delivery times for inputs lengthened and their prices increased at a record pace. The eurozone's annual rate of inflation hit a 13-year high in September and is set to move even higher before the end of the year. However, many economists continue to view the acceleration in price rises as a temporary problem that will be resolved when factories world-wide have had the time to add capacity and meet strong consumer demand.The International Monetary Fund on Wednesday said Europe's major central banks shouldn't rush to raise their key interest rates to tackle the inflation surge.'Our view is that monetary policies in most economies should remain highly accommodative because employment has yet to reach precrisis levels and there are few signs that price increases are translating into broad-based wage pressures,' said Alfred Kammer, head of the International Monetary Fund's European department.Japanese and Australian businesses also report supply shortages and rising costs, but in both countries the surveys of purchasing managers pointed to a pickup in growth as restrictions imposed earlier in the year were eased. The composite PMI for Japan increased to 50.7 in October from 47.9 in September, indicating a return to growth.'With virus cases having receded substantially from the record high levels seen in August, and state of emergency conditions in many prefectures removed at the end of last month, today's Japanese flash PMIs for October cast the economy in a much stronger light than in recent months,' economists at Daiwa Capital Markets wrote in a note to clients.The Australian measure rose to 52.2 in October from 46.0 in September, also pointing to a return to growth after the lifting of restrictions.paul.hannon@wsj.comWrite to Paul Hannon at david.harrison@wsj.compaul.hannon@wsj.com and David Harrison at david.harrison@wsj.com

CME

 CME Group Inc. Cl A Stock Rises Friday, Outperforms Market

Mentioned:

CME

This article was automatically generated by MarketWatch using technology from Automated Insights. 

Shares of CME Group Inc. Cl A (CME) advanced 1.47% to $217.95 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.21% to 35,677.02 and the S&P 500 Index falling 0.11% to 4,544.90. This was the stock's second consecutive day of gains. CME Group Inc. Cl A closed $3.87 below its 52-week high ($221.82), which the company achieved on June 1st. 

The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Intercontinental Exchange Inc. (ICE) rose 1.54% to $131.60, MSCI Inc. (MSCI) rose 1.99% to $649.09, and Nasdaq Inc. (NDAQ) rose 1.44% to $201.72. Trading volume (1.2 M) remained 162,429 below its 50-day average volume of 1.3 M. 

Data source: Dow Jones Market Data, FactSet. Data compiled October 22, 2021. 

-MarketWatch Automation 

(END) Dow Jones Newswires

October 22, 2021 16:44 ET (20:44 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.

To buy

 

SPCE

 

PLRD

 12:55p ET 10/7/2021 - Benzinga

Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today?

Mentioned:

PRLD

• Prelude Therapeutics Inc (NASDAQ: PRLD) has announced data from the dose-escalation portions of Phase 1 trials of PRT543 and PRT811. 
• The data will be featured at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.
• PRT543 demonstrated target engagement and inhibition of PRMT5 functional activity, evidenced by a 69% reduction in serum symmetric dimethylarginine (sDMA) at a dose of 45 mg/5x per week. 
• One complete response (CR) was maintained for over 18 months in a patient with HRD+ ovarian cancer.
• Stable disease (SD) persisting for over six months was seen in five patients, including four with adenoid cystic carcinoma (ACC) and one with uveal melanoma. 
• The most common grade 3 or higher treatment-related adverse events were thrombocytopenia (27%) and anemia (12%), reversible upon treatment interruption. 
• PRT811 demonstrated dose-dependent inhibition of PRMT5 activity, evidenced by an 83% reduction in serum sDMA at 600 mg daily. 
• PRT811 demonstrated signs of preliminary clinical activity, including an IDH1 mutated GBM patient who experienced a partial response (PR) that evolved into a durable CR for more than 13 months.
• One patient with splicing-mutant (SF3B1) uveal melanoma demonstrated SD for more than six months with a 25% tumor regression and remains on treatment. 
• One additional patient (800 mg twice daily) with SF3B1 uveal melanoma had an unconfirmed PR and 47% decrease in target lesion. 
• A patient with triple-negative breast cancer (800 mg QD) demonstrated a 27% decrease in target lesions. 
• Related: Why BofA Is Turning Bullish On Prelude Therapeutics.
• Price Action: PRLD stock is down 33.3% at $19.20 during the market session on the last check Thursday.

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

GTE